@article {MahlerP3386, author = {Donald A. Mahler and Marc Decramer and Anthony D{\textquoteright}Urzo and Heinrich Worth and Tracy White and Vijay Alagappan and Hungta Chen and Karoly Kulich and Nicola Gallagher and Donald Banerji}, title = {Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study}, volume = {42}, number = {Suppl 57}, elocation-id = {P3386}, year = {2013}, publisher = {European Respiratory Society}, abstract = {IntroductionPatients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium, versus placebo (PB) and tiotropium (TIO).MethodIn this 6-wk, multicenter, blinded, placebo-controlled, 3-period, crossover study, patients >=40yrs with moderate-to-severe COPD were randomized to QVA149 110/50{\textmu}g or TIO 18{\textmu}g or PB. Improvements in patient-reported dyspnea via the innovative self-administered computerized (SAC) Baseline and Transition Dyspnea Index (BDI/TDI) and FEV1 AUC0-4h were assessed.Results78 (31.6\%) of the 247 patients randomized had severe COPD. The percentage of patients with severe COPD achieving >=1 point improvement in SAC-TDI total score was higher with QVA149 (41.7\%) compared with TIO (30.0\%; odds ratio 1.66; p=0.185) and PB (21.7\%; odds ratio 2.98; p=0.007). QVA149 provided rapid bronchodilation, with statistically significant (p\<0.001) improvements in FEV1 AUC0{\textendash}4h versus PB and TIO. Least squares mean treatment difference between QVA149-PB and QVA149-TIO were 1.92 (p\<0.001) and 0.76 (p=0.042) for SAC-TDI and 254mL and 92mL (both p\<0.001) for FEV1 AUC0-4h, respectively.ConclusionIn patients with severe COPD, once-daily QVA149 provided clinically meaningful and statistically superior improvements in lung function which translated into better control of breathlessness compared to placebo and tiotropium.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/42/Suppl_57/P3386}, eprint = {https://erj.ersjournals.com/content/42/Suppl_57/P3386.full.pdf}, journal = {European Respiratory Journal} }